HMGB1 and B-cell non-Hodgkin lymphoma: In vivo models of B-cell lymphoma and colorectal cancer demonstrated that melphalan causes immunogenic cell death, determined by surface-exposed calreticulin and release of high-mobility group box 1 (HMGB1) [197].